Segment Information

9 Months Ended

Sep. 30, 2020

Segment Information

Segment Information

14. Segment Information

The Company has two reportable segments-human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is approved by the U.S. FDA for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

The Company's reportable segments net revenues and net loss for the three and nine months ended
September 30, 2020 and 2019 consisted of:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(in thousands)	2020		2019		2020		2019
	(unaudited)				(unaudited)
Revenue from external customers
Human Health	$	2,760	$	957	$	6,748	$	4,185
Animal Health		13		16		61		83
Consolidated Totals	$	2,773	$	973	$	6,809	$	4,268
Segment net loss
Human Health	$	(1,912)	$	(3,955)	$	(6,721)	$	(16,586)
Animal Health		(5,954)		(3,600)		(18,319)		(15,994)
Consolidated Totals	$	(7,866)	$	(7,555)	$	(25,040)	$	(32,580)

The Company's reportable segments assets consisted of the following:

	September 30,		December 31,
(in thousands)	2020		2019
Segment assets	(unaudited)
Human Health	$	33,930	$	32,432
Animal Health		69,466		68,169
Total	$	103,396	$	100,601

The reconciliation of segments assets to the consolidated assets is as follows:

	September 30,		December 31,
	2020		2019
(in thousands)	(unaudited)
Total assets for reportable segments	$	103,396	$	100,601
Less: Investment in subsidiary		(29,241)		(29,241)
Less: Intercompany loan		(37,921)		(34,950)
Consolidated Totals	$	36,234	$	36,410